Hybrid Closed Loop Pivotal Trial in Type 1 Diabetes

Completed · Not applicable

Conditions studied: Type 1 Diabetes

In brief

This study is a single-arm, multi-center, Home and Hotel Clinical Investigation in subjects with type 1 diabetes on insulin pump therapy. The purpose of this study is to demonstrate that the closed loop algorithm that is built into the 670G insulin pump is safe as part of the overall system.

Key facts

Study ID

NCT02463097

Run by

Medtronic MiniMed, Inc.

People needed

124

Starts

2015-06-01

Expected to finish

2018-10-01

Last updated by the study team

2019-04-16

Who can join

Age: 14 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Is age 14 - 75 years at time of screening
• Has a clinical diagnosis of type 1 diabetes for 2 years or more as determined via medical record or source documentation by an individual qualified to make a medical diagnosis
• Is willing to participate in a hotel study for the specified duration of hotel stay.
• Must have companion who will sleep in the same dwelling place every night during the study period and should also be able to call the subject daily in the event the subject is traveling.
• Is willing to perform ≥ 4 finger stick blood glucose measurements daily
• Is willing to perform required sensor calibrations
• Is willing to wear the system continuously throughout the study
• Has a Glycosylated hemoglobin (A1C) value less than 10.0% (as processed by Central Lab) at time of screening visit
• Has TSH in the normal range OR if the TSH is out of normal reference range the Free T3 is below or within the lab's reference range and Free T4 is within the normal reference range.
• Pump therapy for greater than 6 months prior to screening (with or without CGM experience)
• Is willing to upload data from the study pump, must have Internet access and a computer system that meets the requirements for uploading the study pump
• If subject has celiac disease, it has been adequately treated as determined by the investigator
• Is willing to take one of the following insulins and can financially support the use of either of the 2 insulin preparations throughout the course of the study (i.e. co-payments for insulin with insurance or able to pay full amount)
• Humalog® (insulin lispro injection)
• NovoLog® (insulin aspart)
• With history of cardiovascular event 1 year or more from the time of screening must have an EKG within 6 months prior to screening or during screening. If subject has an abnormal EKG, participation is allowed if there is clearance from a cardiologist
• With 3 or more cardiovascular risk factors listed below must have an EKG within 6 months prior to screening or during screening. If subject has an abnormal EKG, participation is allowed if there is clearance from a cardiologist
• Cardiovascular risk factors include:
• Age >35 years
• Type 1 diabetes of >15 years' duration
• Presence of any additional risk factor for coronary artery disease
• Presence of microvascular disease (proliferative retinopathy or nephropathy, including microalbuminuria)
• Presence of peripheral vascular disease
• Presence of autonomic neuropathy
• With history of cardiovascular event 1 year or more from the time of screening must have a stress test within 6 months prior to screening or during run in period. If subject fails stress test, participation is allowed if there is clearance from a cardiologist

You may not qualify if…

• Has a history of 2 or more episodes of severe hypoglycemia, which resulted in any the following during the 6 months prior to screening:
• Medical assistance (i.e. Paramedics, Emergency Room ( ER) or Hospitalization)
• Coma
• Seizures
• Is unable to tolerate tape adhesive in the area of sensor placement
• Has any unresolved adverse skin condition in the area of sensor placement (e.g., psoriasis, dermatitis herpetiformis, rash, Staphylococcus infection)
• Females who are sexually active and able to conceive will be excluded if they are not using an effective method of contraception and do not agree to continue using an effective method of contraception for the duration of the study as determined by investigator.
• Has had any of the following cardiovascular events within 1 year of screening: myocardial infarction, unstable angina, coronary artery bypass surgery, coronary artery stenting, transient ischemic attack, cerebrovascular accident, angina, congestive heart failure, ventricular rhythm disturbances or thromboembolic disease
• Is being treated for hyperthyroidism at time of screening
• Has diagnosis of adrenal insufficiency
• Has had DKA in the 6 months prior to screening visit.
• Has taken any oral, injectable, or intravenous (IV) steroids within 8 weeks from time of screening visit, or plans to take any oral, injectable, or IV steroids during the course of the study
• Actively participating in an investigational study (drug or device) wherein he/she has received treatment from an investigational study drug or investigational study device in the last 2 weeks
• Has been hospitalized or has visited the ER in the 6 months prior to screening resulting in a primary diagnosis of uncontrolled diabetes
• Currently abusing illicit drugs
• Currently abusing marijuana.
• Currently abusing prescription drugs
• Currently abusing alcohol
• Using pramlintide (Symlin), DPP-4 inhibitor, liraglutide (Victoza or other GLP-1 agonists), metformin, canagliflozin (Invokana or other SGLT2 inhibitors) at time of screening
• Has a history of visual impairment which would not allow subject to participate in the study and perform all study procedures safely, as determined by the investigator
• Has elective surgery planned that requires general anesthesia during the course of the study
• Has a sickle cell disease, hemoglobinopathy; or has received red blood cell transfusion or erythropoietin within 3 months prior to time of screening
• Plans to receive red blood cell transfusion or erythropoietin over the course of study participation
• Diagnosed with current eating disorder such as anorexia or bulimia
• Diagnosed with chronic kidney disease that results in chronic anemia

Where it is running

• AMCR Institute — Escondido, California, United States
• Stanford University Medical Center — Palo Alto, California, United States
• Barbara Davis Center for Childhood Diabetes (Adult) — Aurora, Colorado, United States
• Barbara Davis Center for Childhood Diabetes (Pediatric) — Aurora, Colorado, United States
• Yale University School of Medicine — New Haven, Connecticut, United States
• Atlanta Diabetes Associates — Atlanta, Georgia, United States
• Park Nicollet Clinic-International Diabetes Center - Adult and Pediatric — Minneapolis, Minnesota, United States
• University of Virginia — Charlottesville, Virginia, United States
• Rainer Clinical Research Center — Renton, Washington, United States
• Institute of Endocrinology, Sheba Medical Center — Tel Aviv, Israel

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.